Pediatric Epilepsy

Condition Description

A disorder in which nerve cell activity in the brain is disturbed, causing seizures.

Epilepsy may occur as a result of a genetic disorder or an acquired brain injury, such as a trauma or stroke.

During a seizure, a person experiences abnormal behavior, symptoms, and sensations, sometimes including loss of consciousness. There are few symptoms between seizures.

Active Trials

  • TRIAL TITLE: A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

    DESCRIPTION: This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.

    SPONSOR: Praxis Precision Medicines

    INDICATION: Developmental and Epileptic Encephalopathies

    STUDY PROTOCOL: PRAX-562-221

    PHASE: 2

    STATUS: Active

    RECRUITING PATIENTS: Yes

    Inquire About This Trial →

  • TRIAL TITLE: A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

    DESCRIPTION: The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.

    SPONSOR: Takeda

    INDICATION: Epilepsy, Dravet Syndrome (Myoclonic Epilepsy), Lennox-Gastaut Syndrome

    STUDY PROTOCOL: TAK 935-18-001

    PHASE: 2 OL

    STATUS: Active

    RECRUITING PATIENTS: No

Upcoming Trials

Past Trials

  • TRIAL TITLE: A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

    DESCRIPTION: This prospective observational study is designed to assess the individualized baseline disease burden in pediatric participants aged 1 year to 16 years, with early-onset SCN2A-DEE by characterizing and quantifying changes in clinical features over a period of up to 12 months.

    SPONSOR: Praxis Precision Medicines

    INDICATION: SCN2A-Developmental and Epileptic Encephalopathy

    STUDY PROTOCOL: SCN2A-NH1

    PHASE: Observational

    STATUS: Completed

    RERUITING PATIENTS: No

  • TRIAL TITLE: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies (ELEKTRA)

    DESCRIPTION: The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.

    SPONSOR: Ovid Therapeutics, Inc.

    INDICATION: Epilepsy, Dravet Syndrome (Myoclonic Epilepsy), Lennox-Gastaut Syndrome

    STUDY PROTOCOL: TAK 935-2002

    PHASE: 2 DB

    STATUS: Completed

    RERUITING PATIENTS: No